European Primary Care Cardiovascular Society

Lipids

Lowering remnants becomes more important, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Lipid-lowering drug prescription decreases with age but increases with frailty

Literature - June 18, 2019 - Kleipool EEF et al. - Age and Ageing 2019

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

Clinical interest in HDL is historically low, but continued research into HDL yields interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Analysis of 4S data suggest greater benefit of statin therapy in those with inherited high LDL

News - May 29, 2019
An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

Individuals with probable FH but no diagnosis have worse survival compared with those with an FH diagnosis

News - May 31, 2019
A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

Lowering of LDL-c with fixed combination of two non-statin cholesterol-lowering agents in high-risk patients

News - June 7, 2019
A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

EAS 2019 A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

Little attention for remnants in recent decades, unrightful so

News - June 7, 2019
Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.

EAS 2019 Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.

Higher CVD risk with sub-optimal LDL-c lowering in many patients initiating statin therapy

Literature - Apr. 29, 2019 - Akyea RK et al. - Heart 2019

In a primary care patient cohort, >50% of patients initiating statin therapy did not show optimal LDL-c lowering, which significantly increased their risk of future CVD events.

Inverse association between long-term statin adherence and all-cause mortality in ASCVD

Literature - Feb. 20, 2019 - Rodriguez F et al. - JAMA Cardiol 2019
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

Efficacy of statins in primary CVD prevention confirmed in large meta-analysis, but individual benefit-harm profiles vary

Literature - Feb. 19, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

In older individuals statins result in large reduction of major vascular events

Literature - Feb. 11, 2019 - Cholesterol Treatment Trialists’ Collaboration - The Lancet 2019

A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.

EPCCS

European Primary Care Cardiovascular Society

3' education - Feb. 8, 2019

Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.